HIV protease inhibitors are a class of antiretroviral medicines that interfere with an important stage of the HIV life cycle. These medicines block the HIV protease enzyme, preventing newly produced viral proteins from being processed into the functional components required to form mature, infectious virus particles. Protease inhibitors are used as part of combination antiretroviral therapy.
Protease inhibitors work during the budding and maturation stage of the HIV life cycle. After HIV has replicated its genetic material and produced viral proteins, immature viral particles assemble and leave the infected CD4 cell. Protease normally processes precursor proteins into smaller components needed for a functional virus. Blocking this enzyme interferes with viral maturation.
Key functions include:
Examples of protease inhibitors include darunavir and atazanavir. Some older protease inhibitors are no longer commonly used in clinical practice. Current treatment choices depend on factors such as previous treatment, resistance, other medicines, and individual clinical circumstances.
Viral suppression refers to reducing HIV RNA in the blood to very low or undetectable levels through effective antiretroviral treatment. Protease inhibitors can contribute to this process by preventing newly produced HIV from completing its maturation cycle. However, HIV treatment generally uses combinations of medicines that target different stages of viral replication.
Important aspects of their role include:
Some protease inhibitors have pharmacokinetic interactions with other medicines because of their effects on metabolic pathways such as CYP3A4. For this reason, healthcare professionals consider other medicines a person is taking when selecting and managing treatment.
Protease inhibitors are one component of the broader antiretroviral treatment approach. Modern ART uses medicines that interfere with different stages of the HIV life cycle, allowing viral replication to be suppressed effectively. ART does not eliminate latent HIV reservoirs, so continued treatment is important for maintaining viral suppression.
Overall, HIV protease inhibitors have an important role in understanding how antiretroviral medicines interfere with HIV replication. By blocking protease and disrupting viral maturation, they prevent newly formed viral particles from becoming fully infectious. Their use within an appropriate combination treatment regimen can contribute to sustained viral suppression. Current treatment decisions should be made with a qualified healthcare professional because drug interactions, resistance patterns, treatment history, and individual circumstances can affect the appropriate regimen.